Table 1 LVEF changes in RT-induced MCT studies using MRI

Machann

et al., [49]

31

HL

<55% in 23% of patients at 24 years post-RT

-

-

Van Der Velde

et al., [50]

80

HL& NHL

53±5% vs 60±5%, P< 0.001 at 20 years post-RT

-

-

Heggemann

et al., [59]

49

Breast

In 3DCRT with/without chemotherapy group: temporary decrease at 6 months

(59-62%, p=.031)

In 3DCRT without chemotherapy group:

temporary decrease at 6 months

(59-63%, p=.005)

resolved at 12 and 24 months:

(p=0.443)

For IMRT group:

at 24 months follow-up

(60.1-63.6%, p=0.017)

At 6 months:

the whole cohort

(59.2-61.2%, p=0.059)

Goyet

et al., [58]

81

Leukemia, HL, NHL, Sarcoma, and others

-

-

Baseline: 62±8%

One-year: 60±7%

Two-year: 61±6%

Traber

et al., [51]

10

Thoracic malignancies

Half-therapy completion:

(dropped below 50% in 1/10 patients)

after RT completion:

(dropped below 50% in 2/10 patients)

-

-

Bergom

et al., [48]

20

Breast

-

-

Normal range (63% (52-77%)) at 8.3 years post-RT

Takagi

et al., [57]

24

Esophageal

-

-

Normal range

(baseline: 63±9%,

0.5 year follow up: 65±12%,

1.5 year follow up: 61±11%)

Bates

et al., [52]

5

HL

At 5 years: >5% LVEF drop in two patients with

mean cardiac RT dose of ≥ 10 Gy

and a total anthracycline dose

of greater than 250 mg/m2

-

At 5 years: Median LVEF was

60% (52-61%)

Umezawa

et al., [56]

19

Esophagus

-

-

Normal range

(baseline: 60.4±8.9%,

6 months: 62.8±12.7%,

and 1.5 years: 62±10.4%)

Vallabhaneni et al., [54]

11

Lung, breast, lymphoma

-

-

No significant % changes in patients with higher radiation (-10.4±7.7%) or patients with minimal radiation (-8.9±8.6%) at 6 months post-RT

Lideståhl

et al., [53]

21

Lung

-

-

Pre-RT: 69 (63-74) %,

2 months: 69.5 (65.5-74.8) %,

3 months: 70 (63-75) %

Speers

et al., [47]

51

Breast

-

-

No significant changes

of LVEF at 3 months post-RT

Tahir

et al., [55]

66

Breast

-

-

In epirubicin-chemotherapy-based

followed by RT group:

unchanged (at baseline: 60±5%,

therapy completion: 60±6% and

after 13±2 months: 60±6%)

-

-

In left-sided RT only

group:

unchanged (baseline: 62±5%,

therapy completion: 64±6%,

13±2 months: 62±5%)